当前位置:首页 > 文献互助 > 互助详情

Real-World Safety Profile of Xanomeline-Trospium (Cobenfy), the First Muscarinic Agonist Antipsychotic: A Disproportionality Analysis of the FDA Adverse Event …复制

用户dO6Bp_vxHIqQ 1个月前 99 10 已完结

1. 系统已在2026-07-31 12:02:13对应助文件进行删除

2. 如有需要请重新发布求助信息

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI:复制

文献链接:复制

其他信息:

H Farquhar
Available at SSRN 6611902
papers.ssrn.com
Background: Xanomeline-trospium (Cobenfy), the first antipsychotic with a non-dopaminergic mechanism approved in over 30 years, received FDA approval for schizophrenia in September 2024. Its muscarinic M1/M4 agonist mechanism may produce a different adverse event profile compared with conventional antipsychotics, but post-marketing data have not been comprehensively evaluated with active-comparator analyses. We aimed to characterise the safety profile of xanomeline-trospium using …

互助时间线

2026-07-24 13:07:39 [完结求助]

楼主确认了jodie0105应助的文件是正确的, 求助状态变成 已完结

2026-07-24 12:02:13 [上传文件]

jodie0105上传了文件(pdf 278.82 KB), 求助状态变成 待确认

2026-07-24 11:36:21 [发起求助]

最新发布的求助